Valeant Ex-CFO’s Trip From Goldman Sachs to Drugmaker’s Target

  • Drugmaker blames Howard Schiller for `improper conduct'
  • Ex-interim CEO fires back that he won't resign Valeant board

Valeant Management Shakeup: What Comes Next?

Howard Schiller caught flak in the service of Valeant Pharmaceuticals International Inc. just last month. As interim chief executive officer, he defended the drugmaker to a hostile U.S. Congress at a Washington hearing on price gouging.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.